While further analysis is required to determine the contribution of gender and estrogen effects on the increased cancer risks in LRRK2-PD patients, our findings suggest the potential utility of hormonal therapy as a dual preventive measure for PD and cancer. Here, LRRK2 is linked to Parkinson disease.